Prospective Cohort Study on efficacy and safety of transcutaneous minocycline (MINO) injection therapy for patients of simple giant hepatic cysts.
Not Applicable
- Conditions
- Simple giant hepatic cysts
- Registration Number
- JPRN-UMIN000012044
- Lead Sponsor
- ational Center for Global Health and Medicine, Department of Gastroenterology
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
a.Patients who have malignant tumors. b.Patients who have multiple hepatic cysts congenitally such as polycystic kidney disease. c.Patients whose cysts are connected to vessels and bile ducts d.Patients who have more serious disease compared to simple giant hepatic cysts.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome is to research the recurrence rate of simple giant hepatic cysts. The recurrence case is defined as follows; -Patients who have abdominal distension -Patients who have prominent tendency to large in cyst size -Patients who have liver dysfunction -Patients who have bleeding and infection in hepatic cysts -Patients who have risk of hepatic cyst rupture -Patients who have acute abdomen due to torsion -Patients who have dilatation of bile ducts The recurrence rate will be calculated as accumulated recurrence rate for 3 years.
- Secondary Outcome Measures
Name Time Method The secondary outcome is reduction rate of cysts at each evaluation period. The reduction rate will be calculated by cyst volume based on CT results comparing at the time of pre-treatment to post- treatment. We will evaluate the changes in symptoms between pre-treatment and post-treatment.